Loading
Led the ATTRACTION-2 nivolumab trial and the SPOTLIGHT zolbetuximab trial, two of the defining gastric cancer studies of the decade.
Yoon-Koo Kang is Professor of Medical Oncology at Asan Medical Center in Seoul, specialising in gastric cancer and gastrointestinal stromal tumours. He led ATTRACTION-2, which established the PD-1 antibody nivolumab in late-line gastric cancer in Asia, and SPOTLIGHT, which established zolbetuximab as the first Claudin 18.2-directed therapy, two of the defining gastric cancer studies of the decade. His publications include the ATTRACTION-2 trial of nivolumab in heavily pretreated gastric or gastro-oesophageal junction cancer and the SPOTLIGHT trial of zolbetuximab plus mFOLFOX6 in Claudin 18.2-positive disease. He also led imatinib and other KIT-directed GIST studies.
Shares Asan Medical Center, SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2.
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2, Nivolumab.
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
Shares SPOTLIGHT & GLOW, SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer, Zolbetuximab, Claudin 18.2.
Shares SPOTLIGHT & GLOW, Zolbetuximab, Gastric & gastro-oesophageal junction cancer.
Shares Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
Shares Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
Shares KIT, Imatinib, Sarcomas (soft tissue, bone, GIST).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/